

AiPlex™ CTDplus

Connective Tissue Disease Microarray Solution



Designed to provide comprehensive CTD diagnostic insights and workflow efficiency

Autoimmune connective tissue diseases (CTD) are complex disorders that may present with a wide spectrum of non-specific manifestations and its differential diagnosis remain clinically challenging.¹ These difficulties frequently result in prolonged times between symptoms onset and diagnosis.¹ Evaluation of multiple autoantibodies may assist clinicians in the assessment of these conditions.

Our targeted menu covers 15 markers in one panel.²⁻¹⁰

In development, subject to regulatory authorizations.

CTD

DFS70/LEDGF

Anti-DFS70 confirms specific anti-nuclear antibodies pattern observed in immunofluorescence.

RA

CCP

Anti-CCP in combination with other markers can help identify connective disease comorbidity.

SLE

dsDNA, Sm, Sm/RNP, Chromatin

Anti-Chromatin improves the sensitivity of SLE detection. Anti-Ribosomal P is associated with neuro-psychiatric SLE.

IIM

Jo-1

Anti-Jo-1 are the only autoantibodies included in the current IIM classification criteria.

MCTD

U1RNP and Sm/RNP

Anti-U1RNP and anti-Sm/RNP help to differentiate MCTD.

SjS

SS-A (Ro60), SS-B (La), TRIM21 (Ro52)

Differentiating anti-SS-A 60 from TRIM21 (Anti-SSA 52) is important as TRIM21 may be associated with interstitial lung disease.

SSc

CENP-B, Scl-70, RNA Pol III

These three markers aid the differentiation between diffuse and limited form of SSc.

IIM: Idiopathic inflammatory myopathies
MCTD: Mixed connective tissue disease
RA: Rheumatoid arthritis

SjS: Sjögren's syndrome
SLE: Systemic lupus erythematosus
SSc: Systemic sclerosis

Fast, Easy, Comprehensive



Includes most of the key markers recommended by clinical guidelines (ACR and EULAR) ²⁻⁸

As the prevalence of autoimmune rheumatic disorders such as RA will continue to grow,¹¹ the demand for high-throughput testing solutions will increase. Autoantibody panels may also help identify common comorbidities within connective diseases. Results for anti-dsDNA and Anti-CCP are standardized against WHO standards in IU/ml, while other markers are assessed semi-quantitatively.



Generates multiple insights in one report with only 10 µl patient sample. One microarray provides up to 15 individual results.



Reduces hands-on time and storage space with ready to use, concentrated onboard reagents and buffers.



Saves time while avoiding human errors with a standardized master curve embedded into RFID* tags, included with all reagents and microarrays.



Shares key reagents with other panels, enabling combined autoimmunity, allergy, and further testing.

* RFID: Radio Frequency Identification



AiPlex CTDplus, running on the MosaiQ platform, is designed to reduce the time to results for patients with CTD.



Simple Workflow

- Patients sample in, results out in one single step
- QC and calibration embedded



Fast Results

- Results within one day
- One sample tube (low volume) for multiple tests



Actionable Insights

- Panels help streamline clinical decision-making for physicians
- Comprehensive panels simplify complex testing pathways

¹ Kernder A. Rheumatol Int. 2023;43(8):1453.

² Aringer M. Ann Rheum Dis. 2019;78:1151.

³ Shiboski CH. Arthritis Rheumatol. 2017;69(1):35.

⁴ Lundberg IE. Arthritis Rheumatol. 2017;69(12):2271.

⁵ Alarcón-Segovia D. J Rheumatol. 1989;16(3):328.

⁶ Tanaka Y. Modern Rheumatology. 2021;31(1):29.

⁷ van den Hoogen F. Arthritis Rheum. 2013;65(11):2737.

⁸ Aletaha D. Arthritis Rheum. 2010;62(9):2569.

⁹ Decker P. Eur J Intern Med. 2021;91:45-52

¹⁰ Mahler M. J Immunol Res. 2014;2014:315179.

¹¹ GBD. Lancet Rheumatol. 2023;5(10):e594-e610



Find out more!

© AliveDx Suisse SA, 2024. The AliveDx logo, AliveDx, AiPlex and MosaiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. In development subject to regulatory authorization. GFD# 0.0120.v1

AliveDx